Anixa Biosciences has obtained a composition-of-matter patent in Australia protecting its breast cancer vaccine technology through 2040. This patent, licensed from Cleveland Clinic, covers a novel preventive and therapeutic vaccine targeting human α-lactalbumin, a protein linked to breast cancer. The vaccine showed promising Phase 1 trial results, meeting safety and immune response goals. The new patent strengthens Anixa's global intellectual property portfolio, supporting future regulatory approvals, partnerships, and commercialization efforts in markets with rising breast cancer rates.
Anixa Biosciences' breast cancer vaccine patent news is presented here with Pluang's Health-sector market data as context. Among 95 Health-sector US stocks on Pluang, 55 rose and 26 fell today. For example, ClearPoint Neuro Inc (CLPT) gained 1.52% to USD 14.04 with a typical hold time of 10 days, contrasting with Canopy Growth Corp (CGC) which dropped 1.54% to USD 0.92 and a 38-day hold time. This snapshot is as of Sep 21, 2026 18:51 WIB.
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
Rothschild & Co Redburn raised Microsoft's price target from $400 to $440 following strong fiscal 2026 results, with revenue up 18% to $331.8 billion and net income rising 31% to $133.7 billion, driven by cloud and AI demand. Despite the target hike,...
